Arch Therapeutics Inc (ARTH)

[jsmith123343]

Someone earlier mentioned 'late summer' as now Sept/Oct...I really think that is incorrect.
CEO said 'late summer' when he presented in early June. Last patient checkup was early July. For 46 patients, one month is way enough time to get stats, and present data beginning to mid August. CE approval will come sometime mid to late September.

If they need to do another trial for internal bleeding, that would start later in 2016. They also are applying for PMA with FDA.

My estimation is stock over $1 by Aug end, over $1.5 by end of year. This is taking into account bit of dilution - maybe another $4 million offering. Warrants sold recently should have got them some $.